41 results about "Central sleep apnea" patented technology

Method and apparatus for the treatment of cardiac failure, Cheyne Stokes breathing or central sleep apnea are disclosed. A subject is provided with ventilatory support, for example positive pressure ventilatory support using a blower and mask. Respiratory airflow is determined. From the respiratory airflow are derived a measure of instantaneous ventilation (for example half the absolute value of the respiratory airflow) and a measure of longterm average ventilation (for example the instantaneous ventilation low pass filtered with a 100 second time constant). A target ventilation is taken as 95% of the longterm average ventilation. The instantaneous ventilation is fed as the input signal to a clipped integral controller, with the target ventilation as the reference signal. The output of the controller determines the degree of ventilatory support. Clipping is typically to between half and double the degree of support that would do all the respirator work. A third measure of ventilation, for example instantaneous ventilation low pass filtered with a time constant of 5 seconds, is calculated. Ventilatory support is in phase with the subject's respiratory airflow to the fuzzy extent that this ventilation is above target, and at a preset rate conversely.

A system for reducing central sleep apnea (CSA) is described in which certain methods of increasing a patient's rebreathing during periods of the sleep cycle are used. By increasing rebreathing during periods of overbreathing, the over-oxygenation which typically results from the overbreathing period can be reduced, thus reducing the compensating underbreathing period and effectively reducing the loop gain associated with the central sleep apnea. Nasal occlusion and a leak resistant oral interface provide control for gas leaks from a patent interface.

A method of treating or preventing snoring, obstructive sleep apnea (OSA) and/or central sleep apnea (CSA) comprises administering a pharmacologically effective amount a salt of acetylhomotaurine (AcHT) such as calcium acamprosate (CA) to a patient. Also disclosed is the use of AcHT and CA for the manufacture of a medicament for treating or preventing snoring, OSA and/or CSA and of a diagnostic device, kit or composition; a protective patch comprising AcHT or CA; and a pharmaceutical composition comprising AcHT or CA and an agent capable of alleviating the effects of snoring OSA and/or CSA, in combined amounts effective in the treatment of snoring OSA and/or CSA, and a carrier.

Disclosed herein are breathing disorder identification, characterization and diagnosis methods, devices and systems. In general the disclosed methods, devices and systems may rely on the characterization of breath sound amplitudes, periodic breath sounds and/or aperiodic breath sounds to characterize a breathing disorder as obstructive (e.g. obstructive sleep apnea - OSA) or non-obstructive (e.g. central sleep apnea - CSA).

A wireless implantable system is provided that is externally powered and comprises of a closed-loop feedback for treating both patients with obstructive and central sleep apnea. A method is provided for treating sleep apnea using an implantable device. The method comprises sensing an inspiration (IN) signal representative of inspiration experienced by a patient from a respiratory surrogate signal and sensing a respiratory effort (RE) signal representative of an amount of effort exerted by the patient during respiration. The method also comprises analyzing the inspiration signal relative to an IN baseline, that corresponds to normal respiratory behavior, to identify an IN indicator, analyzing the RE signal relative to an RE baseline, that corresponds to a normal amount of respiratory exerted by the patient, to identify an RE indicator, declaring a central sleep apnea (CSA) state or an obstructive sleep apnea (OSA) state based on the IN and RE indicators, and delivering at least one of a CSA therapy when the CSA state is declared or an OSA therapy when the OSA state is declared.

The present invention relates to a method for treating impaired respiratory function in a human patient suffering from sleep apnea, such as central sleep apnea or obstructive sleep apnea, comprising administering to said patient an effective amount of gaboxadol per day.

The invention discloses a method and device for treating central sleep apnea. The method includes the following steps that 1, surface electromyogram signals of respiratory muscles are collected; 2, filtering is carried out; 3, enveloping calculation of the surface electromyogram signals is carried out; 4, respiratory electromyogram sign signals are generated; 5, the oxyhemoglobin saturation of a patient is detected, wherein an oxyhemoglobin saturation probe clamped to a finger can be used; 6, if no respiratory electromyogram sign signal is collected in continuous 10 seconds and the decrease rate of oxyhemoglobin saturation exceeds 3%, external pacing is carried out on respiratory muscles. The method is applied to the device. The method and the device are precise, effective and good in use effect.

The invention discloses a method and device for treating central sleep apnea. The method comprises the following steps of 1) collecting surface electromyographic signals of respiratory muscles; 2) filtering by a filter; 3) performing envelope calculation on the surface electromyography signals; 4) generating electric mark signals of the respiratory muscles; 5), detecting blood oxygen saturation ofa patient by using a blood oxygen saturation probe clamped to a finger; 6), if the electric mark signals are not sampled in 10 seconds and the blood oxygen saturation drops by 3% or above, conductingexternal pacing on the respiratory muscles. The method is applied to the device. The method and device have the advantages of being accurate and effective, and the use effect is good.

A method is provided for reducing the risk of sustaining a traumatic brain injury caused by a traumatic event that includes identifying a subject at risk of sustaining a traumatic brain injury, and then precisely increasing the partial pressure of carbon-dioxide (CO₂) in the blood of the subject (pCO₂). This method can be applied to raise the CO₂ and pCO₂ to improve orthostatic hypotension in conditions such as dysautonomias (like Positional Orthostatic Tachycardic Syndrome POTS) and to facilitate the drive to breathe in conditions like Central Sleep Apnea (CSA) and Sudden Infant Death Syndrome (SIDS). The pCO₂ of the person is increased by placing a breathing apparatus over the mouth of the person through which the person must breath, wherein the breathing apparatus includes an enlarged dead space volume in which expired CO₂ collects to be inhaled or re-breathed by the person on the next inhalation.

The invention discloses a method and device for treating the central sleep apnea. The method includes the following steps that: 1) the surface electromyographic signals of respiratory muscles are collected; 2) filtering is carried out, so that undesired components can be filtered out; 3) the envelope of the surface electromyographic signals is calculated; 4) respiratory muscle electric mark signals are generated; 5) the blood oxygen saturation of a patient is detected, and a blood oxygen saturation probe which clamps a finger can be adopted; and 6) if respiratory muscle electric mark signals have not been sampled for 10 consecutive seconds, and the blood oxygen saturation is reduced by more than 3%, in vitro pacing is performed on the respiratory muscles. The method and device for treating the central sleep apnea of the invention have the advantages of high accuracy, high effectiveness and good use effect.

This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors. These brain networks, which are involved in regulation of breathing, and cognitive abilities related to memory impairment, such as is observed in a variety of dementias, in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's disease, schizophrenia, respiratory depression, sleep apneas, attention deficit hyperactivity disorder and affective or mood disorders, and in disorders wherein a deficiency in neurotrophic factors is implicated, as well as in disorders of respiration such as overdose of an alcohol, an opiate, an opioid, a barbiturate, an anesthetic, or a nerve toxin, or where the respiratory depression results form a medical condition such as central sleep apnea, stroke-induced central sleep apnea, obstructive sleep apnea, congenital hypoventilation syndrome, obesity hypoventilation syndrome, sudden infant death syndrome, Rett syndrome, spinal cord injury, traumatic brain injury, Cheney-Stokes respiration, Ondines curse, Prader-Willi's syndrome and drowning. In a particular aspect, the invention relates to compounds useful for treatment of such conditions, and methods of using these compounds for such treatment.

This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors. These brain networks, which are involved in cognitive abilities related to memory impairment, such as is observed in a variety of dementias, in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's disease, schizophrenia, sleep apneas, attention deficit hyperactivity disorder and affective or mood disorders, and in disorders wherein a deficiency in neurotrophic factors is implicated, as well as conditions such as stroke-induced central sleep apnea, obstructive sleep apnea, congenital hypoventilation syndrome, obesity hypoventilation syndrome, sudden infant death syndrome, Rett syndrome, spinal cord injury, traumatic brain injury, Cheney-Stokes respiration, Ondines curse, Prader-Willi's syndrome and drowning. In a particular aspect, the invention relates to bicyclic amide compounds useful for treatment of such conditions, and methods of using these compounds for such treatment.